Evidence map›Paper›PMID 35679462›Full record

ArticleBlood advances2022

Developing and validating a mortality prediction model for ICH in ITP: a nationwide representative multicenter study.

Shan Chong, Peng Zhao, Rui-Bin Huang, Hu Zhou, Jia-Ning Zhang, Ming Hou, Yi Liu, Hong-Xia Yao, Ting Niu, Jun Peng and 30 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in Blood advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. A hematoma location-based nomogram for individualized prediction of thalamic pain after spontaneous thalamic hemorrhage.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. How we treat primary immune thrombocytopenia in adults.Journal of hematology & oncology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

40 authors at 20 institutions in 1 country.

Shan ChongPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Peng ZhaoPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Rui-Bin HuangDepartment of Hematology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Hu ZhouDepartment of Hematology, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
Jia-Ning ZhangPeking University Cancer Hospital and Institute, Beijing, China.
Ming HouDepartment of Hematology, Qilu Hospital, Shandong University, Jinan, China.
Yi LiuDepartment of Geriatric Hematology, Chinese People's Liberation Army General Hospital, Beijing, China.
Hong-Xia YaoDepartment of Hematology, Hainan General Hospital, Haikou, China.
Ting NiuDepartment of Hemotology, West China Hospital, Sichuan University, Chengdu, China.ORCID 0000-0003-1580-1014
Jun PengDepartment of Hematology, Qilu Hospital, Shandong University, Jinan, China.ORCID 0000-0003-1434-1490
Ming JiangDepartment of Hematology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Yan-Qiu HanDepartment of Hematology, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.
Jian-Da HuFujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, China.
Ze-Ping ZhouDepartment of Hematology, The Second Affiliated Hospital of Kunming Medical University, Kunming, China.
Lin QiuDepartment of Hematology, The First Hospital of Jilin University, Changchun, China.
Lian-Sheng ZhangDepartment of Hematology, Lanzhou University Second Hospital, Lanzhou, China.
Xin WangDepartment of Hematology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.ORCID 0000-0001-8051-1481
Hua-Quan WangDepartment of Hematology, Tianjin Medical University General Hospital, Tianjin, China.
Ru FengDepartment of Hematology, Beijing Hospital, Ministry of Health, Beijing, China.
Lin-Hua YangDepartment of Hematology, Second Affiliated Hospital of Shanxi Medical University, Taiyuan, China.
Liang-Ming MaDepartment of Hematology, Affiliated Shanxi Big Hospital of Shanxi Medical University, Taiyuan, China.
Shun-Qing WangDepartment of Hematology, Guangzhou First People's Hospital, Guangzhou, China.
Pei-Yan KongXinqiao Hospital, The Third Military Medical University, Chongqing, China.
Wen-Sheng WangDepartment of Hematology, Peking University First Hospital, Beijing, China.
Hui-Ping SunRui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jing SunNanfang Hospital, Nanfang Medical University, Guangzhou, China.
He-Bing ZhouBeijing Luhe Hospital, Capital Medical University, Beijing, China.
Tie-Nan ZhuDepartment of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Li-Ru WangFuxing Hospital, Capital Medical University, Beijing, China.
Jing-Yu ZhangDepartment of Hematology, Second Hospital of Hebei Medical University, Shijiazhuang, China; and.
Qiu-Sha HuangPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Hai-Xia FuPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Ye-Jun WuPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Yue-Ying LiKey Laboratory of Genomic and Precision Medicine, Collaborative Innovation Center of Genetics and Development, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China.
Qian-Fei WangKey Laboratory of Genomic and Precision Medicine, Collaborative Innovation Center of Genetics and Development, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China.
Qian JiangPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Hao JiangPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Jin LuPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Xiao-Jun HuangPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Xiao-Hui ZhangPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Peking University · CNBeijing Institute of Genomics · CNHebei Medical University · CNQilu Hospital of Shandong University · CNShanxi Medical University · CNZhengzhou University · CNArmy Medical University · CNBeijing Hospital · CNCapital Medical University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNChinese People's Liberation Army · CNFujian Medical University · CNGuangzhou First People's Hospital · CNHainan General Hospital · CNInner Mongolia Medical University · CNJilin University · CNKunming Medical University · CNLanzhou University Second Hospital · CNNanchang University · CNNanfang Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intracranial hemorrhage (ICH) is a rare and life-threatening hemorrhagic event in patients with immune thrombocytopenia (ITP). However, its mortality and related risk factors remain unclear. Herein, we conducted a nationwide multicenter real-world study of ICH in adult ITP patients. According to data from 27 centers in China from 2005 to 2020, the mortality rate from ICH was 33.80% (48/142) in ITP adults. We identified risk factors by logistic univariate and multivariate logistic regression for 30-day mortality in a training cohort of 107 patients as follows: intraparenchymal hemorrhage (IPH), platelet count ≤10 × 109/L at ICH, a combination of serious infections, grade of preceding bleeding events, and Glasgow coma scale (GCS) level on admission. Accordingly, a prognostic model of 30-day mortality was developed based on the regression equation. Then, we evaluated the performance of the prognostic model through a bootstrap procedure for internal validation. Furthermore, an external validation with data from a test cohort with 35 patients from 11 other centers was conducted. The areas under the receiver operating characteristic (ROC) curves for the internal and external validation were 0.954 (95% confidence interval [CI], 0.910-0.998) and 0.942 (95% CI, 0.871-1.014), respectively. Both calibration plots illustrated a high degree of consistency in the estimated and observed risk. In addition, the decision curve analysis showed a considerable net benefit for patients. Thus, an application (47.94.162.105:8080/ich/) was established for users to predict 30-day mortality when ICH occurred in adult patients with ITP.

Indexed as

Purpura, Thrombocytopenic, IdiopathicAdultCerebral HemorrhageGlasgow Coma ScaleHumansIntracranial HemorrhagesROC Curve

Identifiers

PMID35679462
PMCPMC9327537
OpenAlexW4281965033

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.